Product
Advertisement
One - Stop Research Support for CAR - NK Therapy
CARNK cell therapies are novel therapeutic options developed with the aim to overcome some limitations of CART cell therapies, such as therapy induced side effects. CARNK cells exhibit higher cytolytic activity than memory T cells and untransduced NK cells; thus, being more effective in killing tumor cells. Currently, over 800 CART and 28 CARNK cell clinical trials are being conducted worldwide.
As a global leading supplier of bioreagents and CRO services for the biopharmaceutical field, Sino
Biological provides comprehensive solutions for CARNK cell therapy development. Our reagents and services can support our customers from early target discovery to the preclinical phase of research and development.
About Sino Biological
Sino Biological is an international reagent supplier and contract research service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research. For example, Sino Biological has a wealth of viral antigens (Provir®) and corresponding antibodies, with one of the world’s Extensive collections. Sino Biological is also a well-recognized, qualified source of recombinant cytokines and high-quality GMP-grade cytokines. In addition, Sino Biological offers contract research production services for the custom development of full length, bioactive proteins and high-affinity antibodies, along with other services. To learn more about Sino Biological visit www.sinobiological.com, follow us on LinkedIn or @SinoInc on Twitter.
Interested in seeing more content from Sino Biological?
Discover all their latest news, webinars, products and more by clicking the link below.
